Here’s a head-scratcher: A 2017 paper examining why long space flights can cause eye damage has been taken down, with a brief note saying NASA, which sponsored the research, asked for the retraction because of “security concerns.”
According to the first author, the paper included information that could identify some of the astronauts that took part in the study — namely, their flight information. Although the author said he removed the identifying information after the paper was online, NASA still opted to retract it. But a spokesperson at NASA told us the agency did not supply the language for the retraction notice. The journal editor confirmed the paper was retracted for “research subject confidentiality issues,” but referred a question about who supplied the language of the notice back to NASA.
Now lawyers are involved.
So we still have some questions about this one. Here’s what we do know.
When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year. And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of 1,000 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at email@example.com.
A journal is investigating research by a group in Australia, after receiving “serious allegations” regarding a 2017 paper about treating eye burns.
The journal, Frontiers in Pharmacology, has issued an expression of concern (EOC) for the 2017 paper while it investigates. The notice does not specify the nature of the allegations. Meanwhile, several other papers by the three researchers, based at Deakin University in Geelong, Australia, have also come under scrutiny. Late last month, Frontiers in Pharmacology retracted a 2015 paper by Kislay Roy, Rupinder Kanwar, and Jagat R Kanwar, citing image duplication. A 2015 paper in Biomaterials received a correction in May 2017, again flagging image duplication.
Roy, the first author on the papers, is a postdoctoral research fellow; Rupinder Kanwar, a middle author, is a senior lecturer; and Jagat R Kanwar, the corresponding author on all three, is head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research.
Gearóid Ó Faoleán, the ethics and integrity manager at Frontiers in Pharmacology, explained that the investigation into the flagged article is ongoing and the EOC “must serve as the extent of our public statement for the present.”
A journal has retracted a paper after the university notified the editors that the authors presented the gruesome details of a patient who they didn’t directly treat.
But the paper’s corresponding author disputes that claim, arguing that the first author — a radiologist, who has since passed away, provided a crucial diagnosis in this case. We’ve tried to track down the doctors who lodged a complaint about the paper, alleging they were “actually involved in the original patient treatment,” but have so far been unsuccessful.
The paper describes an unfortunate accident during which a man fell from his tractor and stabbed himself in the eye on part of the machine. Initially, doctors could not locate the eye and “believed it to have been completely destroyed,” and discharged the patient after seven days. One week later he was back, complaining of headaches — and doctors found the eye embedded deep inside the skull, intact.
A publisher in the Netherlands has retracted 13 published studies and withdrawn 52 that were under consideration (but not yet published) after learning that someone illegally accessed its workflows to add fake authors and manipulate text.
According to Seyyed Mohammad Miri, the founder, CEO, and managing director of Kowsar Publishing, the 13 retracted papers all included extra authors added by the same Internet Protocol (IP) address. Cyber police in Iran found the same IP address had also accessed the 52 other papers, which were in various stages of the publishing process (such as peer review) and not yet online, Miri told Retraction Watch.
Most of the authors on the 13 retracted papers are based in institutions in Iran; some were co-authors on the 58 retractions recently issued as part of a mass clean-up by publishers BioMed Central and Springer, citing fake reviews, adding inappropriate authors, and plagiarism.
A biologist at the University of Georgia has lost a paper after an investigation revealed she had tampered with three images.
In 2014, Azza El-Remessy notched three retractions for a series of image errors. Now, a fourth retraction notice, and an expression of concern, explain there has been an investigation into her work. The investigation — conducted by two Georgia institutions, along with the Charlie Norwood Veterans Affairs Medical Center, where El-Remessy has additional appointments — has found evidence of misconduct.
A former graduate student at the University of Colorado Denver has gained three retractions and two expressions of concern (EOC), following an institutional probe into his work.
Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.
We’ve since discovered more notices, bringing his total to seven retractions and three EOCs.
Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.
A JAMA journal has quickly issued a correction for a 2016 paper after the author failed to mention several relevant conflicts of interest. Normally, we’d see this as a run-of-the-mill correction notice, but since we reported last week that a journal retracted a paper for omitting pharma funding, we got to wondering: Is failure to disclose a conflict of interest a retractable offense?